<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025493</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068966</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S0029</secondary_id>
    <nct_id>NCT00025493</nct_id>
  </id_info>
  <brief_title>S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer</brief_title>
  <official_title>Single Agent Docetaxel for Metastatic Breast Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger Than 60 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating older women who&#xD;
      have metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of treating elderly women with metastatic breast cancer with&#xD;
           docetaxel.&#xD;
&#xD;
        -  Determine the overall survival, 2-year survival, and response (confirmed and unconfirmed&#xD;
           complete and partial) in patients treated with this drug.&#xD;
&#xD;
        -  Determine the toxicity and tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine the feasibility of using standardized self-report measures of comorbidity,&#xD;
           depression, and functional status in elderly cancer patients.&#xD;
&#xD;
        -  Determine the parameters of clinical pharmacology of this drug in elderly patients and&#xD;
           in patients under 60 years of age.&#xD;
&#xD;
        -  Determine, preliminarily, the genetic polymorphisms and gene expression levels of&#xD;
           enzymes involved in drug metabolism and resistance in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to age (70 and over vs under 60).&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 80 patients (60 patients age 70 and over and 20 patients&#xD;
      under age 60) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study treatment feasibility</measure>
    <time_frame>monthly for duration of accrual</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at weeks 10 and 19, then every 3 months for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 2 years</measure>
    <time_frame>at weeks 10 and 19, then every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (confirmed and unconfirmed complete and partial response)</measure>
    <time_frame>at weeks 10 and 19, then every 3 months for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and tolerability</measure>
    <time_frame>at week 1, then every 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of standardized self-report measures of comorbidity, depression, and functional status</measure>
    <time_frame>upon completion of patient accrual</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical pharmacologic parameters between elderly patients and patients under 60 years of age</measure>
    <time_frame>upon completion of patient accrual</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Distant metastatic disease confirmed by histology, cytology, or strong clinical&#xD;
                  evidence&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No known brain or CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  70 and over OR&#xD;
&#xD;
          -  Under 60&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT no greater than 1.5 times ULN (2.0 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times ULN (2.0 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated basal cell&#xD;
             or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer in complete remission&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy for breast cancer&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy allowed&#xD;
&#xD;
          -  Prior adjuvant taxanes allowed&#xD;
&#xD;
          -  No other concurrent chemotherapy for breast cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior hormonal therapy in the adjuvant setting or for metastatic disease allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy for breast cancer&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy for breast cancer&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No more than 1 prior regimen for advanced, recurrent, or metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvana Martino, DO</last_name>
    <role>Study Chair</role>
    <affiliation>John Wayne Cancer Institute</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

